The company was founded in 2012 and has been using an integrated development platform based on the combination of a gene therapy-based approach with technologies such as mitochondrial target sequence (MTS) and optogenetics.

GenSight now has two product candidates in clinical trials and is investigating others. Its lead product is GS010, which is in Phase III development for leber hereditary optic neuropathy.